However, in the context of sodium channelopathy mutations, that is, SCN1A, SCN2A, SCN8A, sodium voltage-gated channel beta subunit 1 (SCN1B), SCN2B, SCN3A, and SCN9A, only SCN1A-, SCN2A-, and SCN8A-related epilepsy, which encodes the alpha subunit of the voltage-gated sodium channel NaV1.1, NaV1.2, and NaV1.6, respectively, had emerging evidence suggesting effectiveness for PER in reducing seizure frequency. This evidence concerns the gene SCN1B and epilepsy.